DK1434603T3 - Fremgangsmåde til behandling ved anvendelse af ligand-immunogen-konjugater - Google Patents
Fremgangsmåde til behandling ved anvendelse af ligand-immunogen-konjugaterInfo
- Publication number
- DK1434603T3 DK1434603T3 DK02789173.8T DK02789173T DK1434603T3 DK 1434603 T3 DK1434603 T3 DK 1434603T3 DK 02789173 T DK02789173 T DK 02789173T DK 1434603 T3 DK1434603 T3 DK 1434603T3
- Authority
- DK
- Denmark
- Prior art keywords
- ligand
- pathogenic cells
- immunogen
- population
- immune response
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32579301P | 2001-09-28 | 2001-09-28 | |
US32633201P | 2001-10-01 | 2001-10-01 | |
US39165402P | 2002-06-26 | 2002-06-26 | |
PCT/US2002/030546 WO2003028634A2 (en) | 2001-09-28 | 2002-09-26 | Method of treatment using ligand-immunogen conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1434603T3 true DK1434603T3 (da) | 2010-04-26 |
Family
ID=32738720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02789173.8T DK1434603T3 (da) | 2001-09-28 | 2002-09-26 | Fremgangsmåde til behandling ved anvendelse af ligand-immunogen-konjugater |
Country Status (10)
Country | Link |
---|---|
US (1) | US20030086900A1 (da) |
EP (2) | EP2168598A1 (da) |
JP (1) | JP2005523878A (da) |
KR (1) | KR20040053136A (da) |
AT (1) | ATE451935T1 (da) |
CA (1) | CA2461877A1 (da) |
DE (1) | DE60234782D1 (da) |
DK (1) | DK1434603T3 (da) |
ES (1) | ES2338305T3 (da) |
WO (1) | WO2003028634A2 (da) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
CZ304942B6 (cs) * | 2000-03-31 | 2015-02-04 | Purdue Research Foundation | Léčivo pro zvyšování specifické eliminace populace tumorových buněk a farmaceutický prostředek obsahující konjugát fosfát-FITC nebo fosfát-dinitrofenyl |
ATE427948T1 (de) | 2001-04-24 | 2009-04-15 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
KR20040015234A (ko) * | 2001-05-02 | 2004-02-18 | 펄듀 리서치 파운데이션 | 대식세포 매개된 질환의 치료와 진단 |
EP1414946A2 (en) * | 2001-07-31 | 2004-05-06 | Francesca Granucci | Dendritic cells and the uses thereof in screening cellular targets and potential drugs |
EP1496934A4 (en) * | 2002-04-19 | 2006-08-02 | Endocyte Inc | IMPROVED IMMUNOTHERAPY BY ADJUVANT |
AU2003243226A1 (en) * | 2002-05-15 | 2003-12-02 | Endocyte, Inc. | Vitamin-mitomycin conjugates |
DK1592457T3 (da) | 2003-01-27 | 2012-10-22 | Endocyte Inc | Folat-vinblastin-konjugat som lægemiddel |
JP5010280B2 (ja) * | 2003-02-21 | 2012-08-29 | ハスミ エルエルシー(ディービーエイ シューコーカイ インターナショナル) | ヒトリンパ球由来のワクチンアジュバント |
JP2007526238A (ja) * | 2003-05-06 | 2007-09-13 | パーデュー・リサーチ・ファウンデーション | マクロファージまたは葉酸受容体を標的とする狼瘡治療法 |
JP4989225B2 (ja) * | 2003-09-25 | 2012-08-01 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 核酸親油性接合体 |
US20070148129A1 (en) * | 2003-12-24 | 2007-06-28 | The Walter And Eliza Hall Instiute Of Medical Research | Therapeutic agents and uses therefor |
EP1720568A2 (en) * | 2004-02-19 | 2006-11-15 | Coley Pharmaceutical Group, Inc. | Immunostimulatory viral rna oligonucleotides |
TWI235440B (en) * | 2004-03-31 | 2005-07-01 | Advanced Semiconductor Eng | Method for making leadless semiconductor package |
WO2006080946A2 (en) * | 2004-06-08 | 2006-08-03 | Coley Pharmaceutical Gmbh | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
WO2006012527A1 (en) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
EP1863816B1 (en) * | 2005-03-16 | 2014-06-25 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
DE602006012816D1 (de) | 2005-03-30 | 2010-04-22 | Endocyte Inc | Tifizierung von zellulären folat vitamin rezeptoren |
JP5175723B2 (ja) | 2005-07-05 | 2013-04-03 | パーデュー・リサーチ・ファウンデーション | 単球介在性疾患を治療するための組成物の調製 |
CN103893778A (zh) * | 2005-08-19 | 2014-07-02 | 恩多塞特公司 | 多药物配体缀合物 |
EP2382995A3 (en) * | 2005-08-19 | 2013-09-25 | Endocyte, Inc. | Ligand conjugates of Vinca alkaloids, analogs and derivatives |
US8357671B2 (en) | 2005-11-10 | 2013-01-22 | James Paulson | High affinity Siglec ligands |
WO2007078615A2 (en) * | 2005-12-15 | 2007-07-12 | Cavit Sciences, Inc | Methods and compositions for treatment of cancer |
US8168164B2 (en) | 2006-02-03 | 2012-05-01 | Purdue Research Foundation | Targeted conjugates and radiation |
JP5473336B2 (ja) * | 2006-02-15 | 2014-04-16 | アディウタイド・ファーマスーティカルズ・ゲーエムベーハー | オリゴヌクレオチドの処方に関する組成物および方法 |
EP2109466B1 (en) | 2007-02-07 | 2014-11-12 | Purdue Research Foundation | Positron emission tomography imaging method |
WO2008101231A2 (en) * | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
NZ599239A (en) * | 2007-03-14 | 2013-10-25 | Endocyte Inc | Binding ligand linked drug delivery conjugates of tubulysins |
WO2008148001A2 (en) * | 2007-05-25 | 2008-12-04 | Purdue Research Foundation | Method of imaging localized infections |
AU2008268432B2 (en) * | 2007-06-25 | 2015-01-15 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
PL2187965T3 (pl) | 2007-08-17 | 2020-05-18 | Purdue Research Foundation | Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania |
JP2011500835A (ja) | 2007-10-25 | 2011-01-06 | エンドサイト,インコーポレイテッド | チューブリシン類および調製プロセス |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
WO2013130776A1 (en) | 2012-02-29 | 2013-09-06 | Purdue Research Foundation | Folate receptor alpha binding ligands |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
CA2887727A1 (en) | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
SG10201706618UA (en) | 2012-11-15 | 2017-09-28 | Endocyte Inc | Conjugates for treating diseases caused by psma expressing cells |
EP3495355A1 (en) | 2013-10-18 | 2019-06-12 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
CA3145908A1 (en) * | 2019-07-08 | 2021-01-14 | Purdue Research Foundation | Compounds and methods for the treatment and prevention of fibrotic disease states and cancer |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2816110A (en) * | 1956-11-23 | 1957-12-10 | Merck & Co Inc | Methods for the production of substituted pteridines |
US4314988A (en) * | 1979-10-31 | 1982-02-09 | Baker Instruments Corp. | Folic acid derivatives and process for preparation |
US4713249A (en) * | 1981-11-12 | 1987-12-15 | Schroeder Ulf | Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof |
US4659655A (en) * | 1981-11-25 | 1987-04-21 | Bio-Response, Inc. | Method for isolating product-producing cells |
US5140104A (en) * | 1982-03-09 | 1992-08-18 | Cytogen Corporation | Amine derivatives of folic acid analogs |
IT1203672B (it) * | 1982-05-12 | 1989-02-15 | Harvard College | Proteina ibrida comprendente frammenti proteici collegati da legami peptidici e relativo gene di fusione composizione contenente tale proteina |
NL8401226A (nl) * | 1984-04-16 | 1985-11-18 | Univ Utrecht | Farmaceutisch produkt met anti-tumorwerking; gebruik van een farmaceutisch produkt of van farmaceutische samenstellingen in een anti-tumortherapie. |
US5266333A (en) * | 1985-03-06 | 1993-11-30 | American Cyanamid Company | Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone |
US4681760A (en) * | 1985-04-17 | 1987-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of conferring immunotolerance to a specific antigen |
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
NZ217821A (en) * | 1985-10-10 | 1989-07-27 | Biotech Australia Pty Ltd | Oral delivery system; complex of active agent and vitamin b12 or analogue thereof |
US5117022A (en) * | 1985-10-18 | 1992-05-26 | The Board Of Regents, The University Of Texas System | Hydrophobic cis-platinum complexes efficiently incorporated into liposomes |
JPS6479125A (en) * | 1986-08-13 | 1989-03-24 | Takeda Chemical Industries Ltd | Antitumor agent |
US4971792A (en) * | 1987-03-27 | 1990-11-20 | The Wistar Institute | Monoclonal antibodies against glycolipid antigens |
US5583112A (en) * | 1987-05-29 | 1996-12-10 | Cambridge Biotech Corporation | Saponin-antigen conjugates and the use thereof |
US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4946945A (en) * | 1987-06-23 | 1990-08-07 | Allergy Immuno Technologies, Inc. | Immunotherapy agents for treatment of IgE mediated allergies |
GB8803365D0 (en) * | 1988-02-13 | 1988-03-16 | Ciba Geigy Ag | Antiviral combination |
WO1990009804A1 (en) * | 1989-02-24 | 1990-09-07 | The Regents Of The University Of California | Genetically engineered immunoglobulins |
US5075287A (en) * | 1989-03-03 | 1991-12-24 | Nisshin Oil Mills, Inc. | Muramyl peptide derivatives and immunoregulating compositions containing them |
US5108921A (en) * | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5688488A (en) * | 1989-04-03 | 1997-11-18 | Purdue Research Foundation | Composition and method for tumor imaging |
US5217881A (en) * | 1989-04-25 | 1993-06-08 | Immunex Corporation | Hyperglycosylated cytokine conjugates |
JPH0686375B2 (ja) * | 1989-09-25 | 1994-11-02 | 大塚製薬株式会社 | リポソーム製剤 |
CA2090105A1 (en) * | 1990-08-29 | 1992-03-01 | Jean-Paul Soulillou | Protein polyligands joined to a stable protein core |
US5159079A (en) * | 1991-12-20 | 1992-10-27 | Eli Lilly And Company | 2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids |
US5273965A (en) * | 1992-07-02 | 1993-12-28 | Cambridge Biotech Corporation | Methods for enhancing drug delivery with modified saponins |
US5650398A (en) * | 1992-07-02 | 1997-07-22 | Cambridge Biotech Corporation | Drug delivery enhancement via modified saponins |
DE69306545T2 (de) * | 1992-10-01 | 1997-04-03 | Wellcome Found | Tucaresol als Mittel zur Immunopotentierung |
US5747024A (en) * | 1993-03-08 | 1998-05-05 | Immunex Corporation | Vaccine adjuvant comprising interleukin-15 |
PT689449E (pt) * | 1993-03-19 | 2003-03-31 | Vacsyn Sa | Composicoes para aplicacao em terapeutica humana caracterizadas pela associacao de um peptido de muramilo a uma citoquina |
US5417982A (en) * | 1994-02-17 | 1995-05-23 | Modi; Pankaj | Controlled release of drugs or hormones in biodegradable polymer microspheres |
US5547668A (en) * | 1995-05-05 | 1996-08-20 | The Board Of Trustees Of The University Of Illinois | Conjugates of folate anti-effector cell antibodies |
US5602171A (en) * | 1995-06-07 | 1997-02-11 | Sugen Inc. | Methods of inhibiting phosphatase activity and treatment of disorders associated therewith using naphthopyrones and derivatives thereof |
US6509313B1 (en) * | 1996-02-28 | 2003-01-21 | Cornell Research Foundation, Inc. | Stimulation of immune response with low doses of cytokines |
AU2610097A (en) * | 1996-04-10 | 1997-10-29 | Sangstat Medical Corporation | Cytomodulating conjugates of members of specific binding pairs |
WO1997042347A2 (en) * | 1996-05-06 | 1997-11-13 | Brigham And Women's Hospital | 5-lipoxygenase gene polymorphisms and their use in classifying patients |
US6231859B1 (en) * | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
KR100578317B1 (ko) * | 1997-05-20 | 2006-05-11 | 갈레니카 파마슈티칼스 인크. | 면역보강성 및 면역자극 활성을 갖는 트리테르펜 사포닌유사체 |
US6080725A (en) * | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
AU1095799A (en) * | 1997-10-17 | 1999-05-10 | Philip L. Fuchs | Folic acid derivatives |
BR9907852A (pt) * | 1998-02-12 | 2000-10-24 | Immunivest Corp | Processos para detectar e enumerar células raras e cancerosas em uma população celular mista, para diagnosticar câncer de estágio precoce em um paciente de teste, para determinar a probabilidade de recorrência de câncer em um paciente humano anteriormente tratado de câncer, para distinguir um carcinoma confinado ao órgão de um carcinoma com propriedades metastáticas, para acompanhar a situação de remissão em um paciente humano com câncer que passa pelo tratamento de terapia contra o câncer e para aumentar quantidades de células epiteliais circulantes em uma amostra de sangue, partìcula magnética revestida, composição, conjuntos de teste para avaliar uma amostra de paciente quanto a presença de células raras circulantes, quanto a presença de células de tumor circulantes, quanto a presença de células de câncer de mama circulantes, quanto a presença de células de câncer de próstata circulantes, quanto a presença de células de câncer de cólon circulantes, quanto a presença de células de câncer de bexiga circulantes e para monitorar um paciente quanto a recorrência de câncer, e, fração de sangue periférico enriquecido quanto a células neoplásticas circulantes |
WO2000009075A2 (en) * | 1998-08-14 | 2000-02-24 | Galenica Pharmaceuticals, Inc. | Chemically modified saponins and the use thereof as adjuvants |
US6960449B2 (en) * | 1999-02-10 | 2005-11-01 | Cell Works Diagnostics, Inc. | Class characterization of circulating cancer cells isolated from body fluids and methods of use |
AUPQ014699A0 (en) * | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using nanoparticles |
AUPQ014799A0 (en) * | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using polymers |
AUPQ071299A0 (en) * | 1999-06-02 | 1999-06-24 | Access Pharmaceuticals Australia Pty Limited | Vitamin directed dual targeting therapy |
JP4948728B2 (ja) * | 1999-08-17 | 2012-06-06 | パーデュー・リサーチ・ファウンデーション | 癌診断用抗体 |
ATE324877T1 (de) * | 1999-08-17 | 2006-06-15 | Purdue Research Foundation | Behandlung von metastatischer krankheit |
DE60022665T2 (de) * | 1999-09-25 | 2006-06-22 | Coley Pharmaceutical Gmbh | Immunstimulierende nukeinsäuren |
JP2003510290A (ja) * | 1999-09-27 | 2003-03-18 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 免疫刺激核酸誘導インターフェロンに関する方法 |
US20020039583A1 (en) * | 1999-09-30 | 2002-04-04 | Subjeck John R. | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
WO2001051083A2 (en) * | 2000-01-13 | 2001-07-19 | Antigenics Inc. | Innate immunity-stimulating compositions of cpg and saponin and methods thereof |
CZ304942B6 (cs) * | 2000-03-31 | 2015-02-04 | Purdue Research Foundation | Léčivo pro zvyšování specifické eliminace populace tumorových buněk a farmaceutický prostředek obsahující konjugát fosfát-FITC nebo fosfát-dinitrofenyl |
EP1496934A4 (en) * | 2002-04-19 | 2006-08-02 | Endocyte Inc | IMPROVED IMMUNOTHERAPY BY ADJUVANT |
DK1592457T3 (da) * | 2003-01-27 | 2012-10-22 | Endocyte Inc | Folat-vinblastin-konjugat som lægemiddel |
US20050222068A1 (en) * | 2003-10-23 | 2005-10-06 | Mourich Dan V | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells |
-
2002
- 2002-09-26 DK DK02789173.8T patent/DK1434603T3/da active
- 2002-09-26 CA CA002461877A patent/CA2461877A1/en not_active Abandoned
- 2002-09-26 JP JP2003531970A patent/JP2005523878A/ja active Pending
- 2002-09-26 WO PCT/US2002/030546 patent/WO2003028634A2/en active Application Filing
- 2002-09-26 KR KR10-2004-7004233A patent/KR20040053136A/ko not_active Application Discontinuation
- 2002-09-26 EP EP09179343A patent/EP2168598A1/en not_active Withdrawn
- 2002-09-26 EP EP02789173A patent/EP1434603B1/en not_active Expired - Lifetime
- 2002-09-26 AT AT02789173T patent/ATE451935T1/de not_active IP Right Cessation
- 2002-09-26 ES ES02789173T patent/ES2338305T3/es not_active Expired - Lifetime
- 2002-09-26 DE DE60234782T patent/DE60234782D1/de not_active Expired - Lifetime
- 2002-09-27 US US10/259,006 patent/US20030086900A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20030086900A1 (en) | 2003-05-08 |
JP2005523878A (ja) | 2005-08-11 |
KR20040053136A (ko) | 2004-06-23 |
ES2338305T3 (es) | 2010-05-06 |
WO2003028634A2 (en) | 2003-04-10 |
EP1434603B1 (en) | 2009-12-16 |
EP1434603A2 (en) | 2004-07-07 |
WO2003028634A8 (en) | 2004-07-29 |
EP1434603A4 (en) | 2005-11-30 |
ATE451935T1 (de) | 2010-01-15 |
DE60234782D1 (de) | 2010-01-28 |
CA2461877A1 (en) | 2003-04-10 |
WO2003028634A3 (en) | 2003-10-16 |
EP2168598A1 (en) | 2010-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1434603T3 (da) | Fremgangsmåde til behandling ved anvendelse af ligand-immunogen-konjugater | |
BR0109704A (pt) | Método de tratamento usando conjugados de imunógeno ligando | |
CY1109786T1 (el) | Μεθοδοι για την θεραπευτικη αγωγη ρευματικων ασθενειων με την χρησιμοποιηση ενος διαλυτου μοριου ctla4 | |
DK0651646T3 (da) | Terapeutiske konjugater af toksiner og lægemidler | |
DK0740650T3 (da) | Codrugs som metode til styret transport af lægemiddel | |
EA200501810A1 (ru) | Композиция конъюгированного лекарственного средства | |
BRPI0510315A (pt) | integração de vacinação com conjugado meningocócico | |
DK1545613T3 (da) | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom | |
DK1594542T3 (da) | Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer | |
FR12C0001I2 (fr) | Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b | |
EE200200578A (et) | Antihüpertensiivsete ja antiangiogeensete ainete terapeutilised kombinatsioonid | |
ATE505208T1 (de) | Rezeptorbindende konjugate | |
DE60137146D1 (de) | Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten | |
DK1276501T3 (da) | Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi | |
DE60139954D1 (de) | Immunmodulatorische konstruktionen und ihre verwendung | |
DK1377320T3 (da) | Polynukleotidbindingskomplekser omfattende steroler og saponiner | |
AU2002319223A1 (en) | Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein |